Highlights of ASH 2019

Pittsburgh, PA US
February 7, 2020

The field of hematology has been rapidly evolving. This continuing medical education activity will discuss new developments in the diagnosis and treatment of malignant and non malignant  hematological disorders, as presented at the 2019 Annual Meeting of the American Society of Hematology (ASH).  At this one-day course, faculty will share the latest updates in myeloid  malignancies, lymphoma, leukemia, multiple myeloma, coagulation disorders, and stem cell  transplantation. Through presentations and Q&A, attendees will gain a deeper understanding of emerging treatments available for hematological malignancies and blood disorders and learn how these new therapies can be integrated into daily practice.
 

Target Audience

This conference is intended for primary care physicians, hematologists and medical oncologists, fellows, residents, CRNP’s, PA’s, nurses and all other healthcare providers. 
 

Learning Objectives

  1. Provide an overview and highlight the cutting edge data presented at the 2018 Annual Meeting of the American Society of Hematology (ASH)
  2. Identify updates in molecular abnormalities which can be utilized in the diagnosis, prognosis, risk stratification and therapy selection for patients with myeloid malignancies.
  3. Discuss and assess the relevant clinical trial data in clinical practice which has the potential to improve outcomes in patients with malignant hematologic disorders including Non-Hodgkin's Lymphoma, CLL, and Multiple Myeloma
  4. Review the updates in sequencing strategies in the era of novel immunotherapies, CAR-T, targeted therapies and stem cell transplantation
  5. Discuss the latest advances in coagulation and platelet disorders
Course summary
Available credit: 
  • 5.75 AMA PRA Category 1 Credit™
  • 5.75 Attendance
Course opens: 
10/14/2019
Course expires: 
06/30/2020
Event starts: 
02/07/2020 - 7:30am
Event ends: 
02/07/2020 - 4:30pm
Cost:
$125.00
Rating: 
0
Fairmont Hotel
510 Market Street
Pittsburgh, PA 15222
United States

Conference  Director

Salman Fazal, MD

Assistant Professor, Temple University School of Medicine

Interim Director, Cell Transplantation Program

Allegheny Health Network Cancer Institute

West Penn Hospital

Pittsburgh,  Pennsylvania

 

Planning Committee

John Lister, MD

Chief, Division of Hematology and

Cellular Therapy

Allegheny Health Network Cancer Institute West Penn Hospital

Pittsburgh, Pennsylvania

Judith Brady

Allegheny Health Network

Cancer institute

West Penn Hospital

Pittsburgh, Pennsylvania

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint providership of Allegheny General Hospital and West Penn Hospital Allegheny Health Network Cancer Institute.   Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Allegheny General Hospital designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credits™.   Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 5.75 AMA PRA Category 1 Credit™
  • 5.75 Attendance

Accreditation Period

Course opens: 
10/14/2019
Course expires: 
06/30/2020

Price

Cost:
$125.00
Please login or register to take this course.